Amylyx Pharmaceuticals (NASDAQ:AMLX) Releases Quarterly Earnings Results, Meets Estimates

Amylyx Pharmaceuticals (NASDAQ:AMLX) announced its earnings results on Thursday. The company reported ($0.38) EPS for the quarter, hitting the consensus estimate of ($0.38), FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:

• Avexitide’s Phase III LUCIDITY trial met its primary and all secondary endpoints, including a 55% reduction in the composite rate of level 2 and level 3 hypoglycemic events versus placebo, with a favorable safety profile. Amylyx remains on track to submit an NDA by year-end and is preparing for a potential 2027 launch, subject to FDA review.
• An oversubscribed equity offering generated $545 million in net proceeds, bringing cash and cash equivalents to $768 million at quarter-end. Management said the funds support NDA preparation, launch readiness, and pipeline development.
• The company estimates about 160,000 people in the U.S. live with PBH and reports growing physician interest in treatment options; a PBH-specific ICD-10 code took effect in October. These market-size and demand assessments are based on Amylyx’s analyses and research.
• Operating expenses rose 38% year over year to $49.7 million, reflecting higher trial spending and pre-commercialization costs; stock-based compensation also increased. The higher spending comes as Amylyx scales its commercial organization ahead of a possible launch.
• Beyond avexitide, Amylyx is targeting a 2027 IND filing for AMX0318, while its AMX0114 ALS trial has advanced to enrollment in its fourth dose cohort. The company also reported progress on a research collaboration, but did not provide new efficacy results for these programs.

Amylyx Pharmaceuticals Stock Down 6.1%

NASDAQ:AMLX traded down $1.78 during trading hours on Thursday, hitting $27.62. 2,210,040 shares of the stock were exchanged, compared to its average volume of 1,297,574. The company’s 50 day moving average is $30.15 and its two-hundred day moving average is $20.35. Amylyx Pharmaceuticals has a twelve month low of $10.83 and a twelve month high of $41.14.

Insider Transactions at Amylyx Pharmaceuticals

In other news, insider Camille Bedrosian sold 10,028 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.40, for a total value of $324,907.20. Following the completion of the sale, the insider directly owned 278,064 shares of the company’s stock, valued at approximately $9,009,273.60. This trade represents a 3.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James Frates sold 10,810 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.36, for a total value of $349,811.60. Following the sale, the chief financial officer owned 233,625 shares of the company’s stock, valued at approximately $7,560,105. The trade was a 4.42% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 60,374 shares of company stock valued at $1,815,257 over the last quarter. Corporate insiders own 10.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Guggenheim boosted their price objective on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Tuesday. Robert W. Baird raised their target price on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research note on Wednesday, August 19th. Wolfe Research raised Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 17th. Finally, Mizuho upped their price target on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $44.14.

About Amylyx Pharmaceuticals